My watch list  


News Zyprexa

  • Pipeline antipsychotic drugs to drive next market evolution

    Antipsychotic pipeline developers have been in the spotlight in recent weeks with the announcement of the FDA approval of Johnson & Johnson’s Invega Sustenna (paliperidone palmitate), FDA panel backing for Schering-Plough’s Saphris (asenapine) and the end of Lundbeck and Solvay’s collaboration for d more

  • Analysis of R&D portfolio management

    At the core of portfolio management lies the need to identify and prioritise the most profitable products/projects in the R&D pipeline with the aim of maximising return on investment. For the pharmaceutical industry, the difficulty of quantifying the uncertainties associated with product development more

  • Lilly Outlines Its Strategy to Become the Pharmaceutical Growth Company of the Decade

    Eli Lilly and Company will review with members of the investment community its strategic and operational plans for industry-leading long-term growth. Growth Strategy "Our growth strategy has been to either discover or collaborate with partners on drug candidates with best-in-class or first-in-clas more

Publications Zyprexa


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE